Filing Flows › Acadia Pharmaceuticals (ACAD) › Q3 2026 › vs Q2 2026
Acadia Pharmaceuticals (ACAD) Q3 2026 vs Q2 2026 (quarter over quarter)
Acadia Pharmaceuticals's revenue rose $34.3M (+11%) from $308M in Q2 2026 to $342M in Q3 2026. Operating margin 21.0% against 12.3% (+8.7 pts).
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 21.0% | 12.3% | +8.7 pts |
| Net margin | 15.6% | 10.2% | +5.4 pts |
| Free cash flow margin | 3.0% | 31.1% | -28.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $342M | $308M | $34.3M | +11% |
| Other income, net | $8.7M | $8.6M | $84K | +1% |
| Operating profit | $71.7M | $37.8M | $33.9M | +90% |
| Costs & expenses | $271M | $270M | $450K | +0.2% |
| Pre-tax earnings | $80.4M | $46.5M | $34.0M | +73% |
| Cost of revenue | $35.1M | $28.3M | $6.8M | +24% |
| Research & development | $76.3M | $81.6M | −$5.3M | -6% |
| SG&A | $159M | $160M | −$1.1M | -0.7% |
| Net earnings | $53.5M | $31.5M | $22.0M | +70% |
| Income tax | $26.9M | $15.0M | $11.9M | +80% |
| Operating cash sources | $74.6M | $51.6M | $23.0M | +45% |
| Depreciation & amortization | $3.7M | $3.2M | $496K | +16% |
| Share-based compensation | $17.5M | $16.9M | $511K | +3% |
| Working capital & other | $63.1M | −$49.2M | $112M | — |
| Operating cash flow | $11.5M | $101M | −$89.3M | -89% |
| Free cash flow (OCF − capex) | $10.3M | $95.7M | −$85.4M | -89% |
| Capital expenditures | $1.2M | $5.1M | −$3.8M | -76% |
Questions
How much did Acadia Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Acadia Pharmaceuticals's revenue rose $34.3M (+11%) from $308M in Q2 2026 to $342M in Q3 2026. Operating margin 21.0% against 12.3% (+8.7 pts).